Simulations uncover mechanisms in alpha-synuclein protein buildup
The presence of salt or a molecular crowd may make it more likely for the alpha-synuclein protein, which forms toxic…
Articles by Margarida Maia, PhD
Parkinson’s patients more prone to hospital delirium, study finds
People with Parkinson’s disease are nearly twice as likely to experience delirium during hospital stays as hospitalized older adults…
NeuroOne ablation system launched in US earlier than expected
NeuroOne has begun a limited U.S. commercial launch of its OneRF Ablation System, a device that can be…
Phase 2 trial of NE3107, an anti-inflammatory, may open in summer
BioVie is planning to launch in late summer a Phase 2b clinical trial of NE3107, its investigational anti-inflammatory small molecule,…
MRT-8102 therapy for inflammatory diseases enters preclinical studies
Monte Rosa Therapeutics is running preclinical studies testing MRT-8102, an orally available molecular glue degrader that targets NEK7, a…
Targeting nitrated alpha-synuclein may delay toxic clumping, spread
An antibody that targets a naturally occurring modified form of alpha-synuclein, a protein that forms into toxic clumps in the…
Farming’s use of pesticides and herbicides tied to Parkinson’s risk
People exposed to high levels of the pesticides and herbicides often used in farming have up to a 36% greater…
Application of Parkinson’s therapy IPX203 resubmitted to FDA
Amneal Pharmaceuticals has resubmitted its application for IPX203, an investigational extended-release oral formulation of carbidopa and levodopa for…
Vyalev, steady levodopa/carbidopa infusion, now available in Canada
Vyalev, a brand name for AbbVie’s ABBV-951 (foslevodopa/foscarbidopa), is now available in Canada as a continuous, subcutaneous (under-the-skin) infusion…
Motor function restored in Parkinson’s mice with GT-02287
A once-daily treatment with GT-02287, an oral medication being developed by Gain Therapeutics, protected nerve cells…